Tradegate
25.02.26 | 07:36
3,082 Euro
-2,28 % -0,072
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,060 | 3,174 | 13:04 | |
| 3,122 | 3,186 | 27.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HANSA BIOPHARMA AB: Hansa Biopharma presenting at TD Cowen's 46th Annual Health Care Conference | 1 | Cision News | ||
| 18.02. | Hansa Biopharma AB: Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA | 122 | GlobeNewswire (Europe) | Lund, Sweden, 18 February 2026. Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted... ► Artikel lesen | |
| 11.02. | Hansa Biopharma reports Q4 results | 2 | Seeking Alpha | ||
| 11.02. | Hansa Biopharma AB: Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results | 315 | PR Newswire | Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024.
Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting... ► Artikel lesen | |
| 26.01. | HANSA BIOPHARMA AB: Hansa Biopharma to host Year-end report 2025 conference call | 4 | Cision News | ||
| HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 22.01. | Hansa Biopharma AB: Hansa Biopharma has won the 2025 SwedenBIO Award | 358 | PR Newswire | LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The... ► Artikel lesen | |
| 07.01. | Wedbush initiates coverage on Hansa Biopharma stock with Outperform rating | 1 | Investing.com | ||
| 19.12.25 | Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation | 721 | PR Newswire | The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types... ► Artikel lesen | |
| 19.12.25 | HANSA BIOPHARMA AB: Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference | 2 | Cision News | ||
| 16.12.25 | Hansa Biopharma AB: Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease | 270 | GlobeNewswire (Europe) | Lund, Sweden, 16 December 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM)... ► Artikel lesen | |
| 15.12.25 | Hansa Biopharma AB: Hansa Biopharma announce changes to strengthen European and International organisation | 193 | GlobeNewswire (Europe) | Lund, Sweden, December 15, 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced a reorganization of its European and International Commercial and Medical Affairs operations, effective... ► Artikel lesen | |
| 13.11.25 | HANSA BIOPHARMA AB: Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie's 16th Annual Nordic Healthcare Conference | 2 | Cision News | ||
| 05.11.25 | HANSA BIOPHARMA AB: Hansa at Truist Securities, Stifel, and SEB Healthcare conferences | 5 | Cision News | ||
| 30.10.25 | Hansa Biopharma GAAP EPS of -SEK1.75, revenue of SEK 30.8M | 3 | Seeking Alpha | ||
| 30.10.25 | Hansa Biopharma AB: Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results | 388 | PR Newswire | Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
First clinical data supports imlifidase ability... ► Artikel lesen | |
| 29.10.25 | Hansa Biopharma AB: Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results | 593 | PR Newswire | LUND, Sweden, Oct. 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant... ► Artikel lesen | |
| 29.10.25 | Jefferies backs Hansa Biopharma on U.S. launch hopes after trial success | 5 | Investing.com | ||
| 10.10.25 | HANSA BIOPHARMA AB: Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler-Najjar syndrome who are immune to AAV | 2 | Cision News | ||
| 08.10.25 | HANSA BIOPHARMA AB: Hansa Biopharma to host Q3 2025 interim results conference call | 3 | Cision News | ||
| 07.10.25 | HANSA BIOPHARMA AB: Hansa Biopharma participating in Optimum's 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 | 1 | Cision News |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| MODERNA | 45,160 | -0,41 % | Moderna's combination flu, COVID shot wins over European drug regulators | ||
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,990 | -1,97 % | HEIDELBERG PHARMA AG im strukturellen Gleichgewicht | ||
| CRISPR THERAPEUTICS | 50,50 | -0,98 % | Crispr Therapeutics gains amid takeover speculation | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 661,60 | 0,00 % | Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung | DJ Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung
Von Colin Kellaher
DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| BIONXT SOLUTIONS | 0,386 | -1,28 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| OCUGEN | 1,524 | -0,78 % | Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer | MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the... ► Artikel lesen | |
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INFLARX | 0,774 | -0,71 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| VIVORYON THERAPEUTICS | 1,444 | +0,56 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen |
HANSA BIOPHARMA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,072 (-2,28 %) liegt der Kurs bei 3,082 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HANSA BIOPHARMA AB finden Sie auf Wallstreet Online.